Aclaris Therapeutics Inc
Company Profile
Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Contact
701 Lee Road
Suite 103
WaynePA19087
USAT: +1 484 324-7933
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
stocks
Big four bank holds up in weakening economic conditions
stocks
Our view after Coles’ shares plunge
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,008.90 | 31.70 | 0.35% |
| CAC 40 | 8,029.15 | 18.54 | -0.23% |
| DAX 40 | 25,907.32 | 73.77 | -0.28% |
| Dow JONES (US) | 51,894.27 | 89.71 | -0.17% |
| FTSE 100 | 10,658.43 | 102.90 | -0.96% |
| HKSE | 23,525.97 | 132.65 | 0.57% |
| NASDAQ | 25,427.76 | 263.40 | 1.05% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,720.26 | 21.63 | 0.16% |
| S&P 500 | 7,587.29 | 45.89 | 0.61% |
| S&P/ASX 200 | 8,886.80 | 30.30 | 0.34% |
| SSE Composite Index | 3,608.10 | 29.93 | -0.82% |